Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (OCS) published notifications dated Dec 9, 2025 reporting the vesting and settlement of restricted stock units (RSUs) previously granted to company directors. The notifications name four directors: Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner, and indicate these RSUs vested/settled in December 2025.

These are routine managers' transaction disclosures concerning executive/director compensation events; no financial amounts or additional terms were included in the text provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – OCS

+0.54%

+0.54% News Effect

On the day this news was published, OCS gained 0.54%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement details the vesting and settlement of RSUs previously granted to several directors...

Analysis

This announcement details the vesting and settlement of RSUs previously granted to several directors, continuing Oculis’s pattern of disclosing managerial transactions. It follows recent clinical advances for Privosegtor and sizeable equity financings that strengthened the balance sheet, as well as an F-3 registration for up to 494,259 warrant-linked shares. Investors may focus on how governance, capital structure, and pivotal trials in the PIONEER program evolve from here.

Key Figures

Share price: $20.59 52-week range: $14.00 – $23.08 Cash & ST investments: $182 million +5 more

8 metrics

Share price $20.59 Prior to RSU vesting news; 24h change -5.03%

52-week range $14.00 – $23.08 Price is 10.79% below 52-week high

Cash & ST investments $182 million As of Sept 30, 2025; runway into 2H 2027

Shares in F-3 resale 494,259 shares Ordinary shares registered for resale via warrant-linked F-3

Potential warrant proceeds $6,877,246.59 If all registered warrants are fully exercised in cash

Equity financing gross $110.0 million Underwritten and direct offerings announced Oct 31, 2025

Estimated net proceeds $102.5 million Combined net from underwritten and direct offerings

ACUITY vision gain 18 letters at 3 months Phase 2 ACUITY trial topline result for Privosegtor

Historical Context

5 past events · Latest: Dec 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 03	RSU vest notification	Neutral	+1.1%	Disclosure of RSU vesting and settlement for director Arshad Khanani.
Nov 28	RSU vest notification	Neutral	+0.0%	Manager’s transaction notice for RSU vesting by director Arshad Khanani.
Nov 25	FDA meeting update	Positive	-2.2%	Positive FDA meeting enabling registrational PIONEER program for Privosegtor.
Nov 18	Director share purchase	Neutral	-0.1%	Notification of ordinary share purchase by director Lionel Carnot.
Nov 12	Phase 2 trial data	Positive	+2.1%	Positive Phase 2 ACUITY data for Privosegtor in acute optic neuritis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Oculis news shows mostly aligned reactions: positive Phase 2 data and some governance updates were followed by gains, while one positive FDA-related update saw a mild divergence with a negative move.

Recent Company History

Over the past months, Oculis combined clinical progress with financing and governance disclosures. Positive Phase 2 ACUITY data and initiation of the PIONEER pivotal program for Privosegtor supported its neuroprotective strategy. On Nov 10, 2025, the company detailed sizeable equity offerings and an F-3 registration, bolstering funding. Alongside, multiple notifications of directors’ RSU vesting and share transactions have provided routine transparency on managerial dealings, consistent with today’s RSU-related announcement.

Regulatory & Risk Context

Active S-3 Shelf · $6,877,246.59 · Short Interest: 1.22%

Shelf Active

Short Interest

1.22% of shares outstanding

as of 2026-05-29 Days to cover: 1

Active S-3 Shelf Registration 2025-11-10

$6,877,246.59 registered capacity

An effective Form F-3 shelf filed on Nov 10, 2025 registers the resale of up to 494,259 warrant-linked shares by a selling securityholder. Oculis is not selling shares under this prospectus; it would only receive up to $6,877,246.59 in cash if all registered warrants are fully exercised.

Key Terms

persons discharging managerial responsibilities, RSUs, vesting, settlement

4 terms

persons discharging managerial responsibilities regulatory

"Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities"

Persons Discharging Managerial Responsibilities are the key people in a company who make big decisions, like top managers or executives. Knowing who they are is important because their actions can influence the company’s success or failure, and they are often required to share information about their dealings to ensure transparency for investors and the public.

RSUs financial

"relate to the vesting and settlement of RSUs previously granted to directors"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vesting financial

"relate to the vesting and settlement of RSUs previously granted to directors"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

settlement financial

"relate to the vesting and settlement of RSUs previously granted to directors"

Settlement is the process of completing a financial transaction, like buying or selling a stock, by transferring money and ownership between parties. It ensures that both the buyer gets the asset and the seller gets paid, making the deal official. Without settlement, the transaction wouldn't be finalized or legally recognized.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Attachments

• Notification of managers' transaction - Anthony Rosenberg - December 2025 RSU vest
• Notification of managers' transaction - Christina Ackermann - December 2025 RSU vest
• Notification of managers' transaction - Arshad Khanani - December 2025 RSU vest
• Notification of managers' transaction - Robert Warner - December 2025 RSU vest

FAQ

What did Oculis (OCS) announce on December 9, 2025 about insider transactions?

Oculis disclosed the vesting and settlement of RSUs for four directors in December 2025.

Which Oculis directors had RSUs vest and settle in December 2025 for OCS?

The notifications named Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner.

Does the Oculis (OCS) notice specify the number of shares or value for the December 2025 RSU vesting?

No; the provided notice reports vesting and settlement but does not include share counts or monetary values.

Will the December 2025 RSU vesting disclosures for Oculis (OCS) affect public filings?

Yes; managers' transaction notifications are regulatory disclosures and are filed to report directors' share-related transactions.

Where can investors find the full Oculis (OCS) managers' transaction notifications for December 2025?

Investors can view the individual managers' transaction notifications linked to the company's disclosures or regulatory filings referencing December 2025 RSU vesting.